Eton CEO exercises derivatives, adds 227500 shares
Eton Pharmaceuticals, Inc. President & CEO Sean Brynjelsen reported only equity acquisitions.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Eton Pharmaceuticals, Inc. President & CEO Sean Brynjelsen reported only equity acquisitions. He exercised employee stock options covering 200000.0000 shares of common stock at an exercise price of 1.3700 on July 14, 2026, and converted 27500.0000 shares from restricted stock units on July 12, 2026. After these derivative exercises, he directly holds 1061194.0000 common shares, with no sales, gifts, or tax-withholding dispositions reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option F2 | 200,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 200,000 | $1.37 | $274K |
| Exercise | Restricted Stock Units F1 | 27,500 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 27,500 | -- | -- |
Footnotes (2)
- F1. On July 12, 2022, the reporting person was granted 110,000 restricted stock units which vested in four equal installments beginning July 12, 2023.
- F2. The shares subject to the option vested annually from the date of grant (11-10-2017) in four equal installments.
Key Figures
Key Terms
Employee Stock Option financial
Restricted Stock Units financial
derivative security financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did ETON’s CEO Sean Brynjelsen report in this Form 4?
What option exercise did ETON’s CEO complete on July 14, 2026?
AI-generated analysis. How Rhea-AI works. Not financial advice.